| Literature DB >> 28028462 |
Nahid Safari-Alighiarloo1, Mostafa Rezaei-Tavirani1, Mohammad Taghizadeh2, Seyyed Mohammad Tabatabaei3, Saeed Namaki4.
Abstract
BACKGROUND: The involvement of multiple genes and missing heritability, which are dominant in complex diseases such as multiple sclerosis (MS), entail using network biology to better elucidate their molecular basis and genetic factors. We therefore aimed to integrate interactome (protein-protein interaction (PPI)) and transcriptomes data to construct and analyze PPI networks for MS disease.Entities:
Keywords: Clique analysis; Modularity; Multiple sclerosis; Protein–protein interaction network (PPIN); Topology; Transcriptome
Year: 2016 PMID: 28028462 PMCID: PMC5183126 DOI: 10.7717/peerj.2775
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Figure 1The degree distribution of nodes followed power law distribution.
(A) Degree distribution of differentially expressed genes in CSF QQPPI network. (B) PBMCs QQPPI network. The graph represents a decreasing trend of degree distribution with an increase in the number of links showing scale-free topology.
Hub-bottleneck identification.
Cut-off determination for hubs & number of hubs and bottlenecks.
| Mean (M) | Standard Deviation (S.D) | Cut-off (M + 2*S.D) | Number of hubs | Number of bottlenecks | |
|---|---|---|---|---|---|
| CSF | 4.86 | 7.3 | 19.4 | 56 | 72 |
| PBMCs | 3.89 | 6.06 | 16.01 | 20 | 25 |
Figure 2QQPPI networks generation by mapping of differentially expression genes on PPI data.
(A) CSF QQPPI network. (B) PBMCs QQPPI network. Nodes with high centrality measures are shown by bigger size than others. Green and red nodes represent proteins encoded by up- and down-regulated genes, respectively. Graphical representation of nodes was implemented by “Spring Embedded” layout in Cystoscape.
Modularity analysis.
The list of pathways enriched in modules for CSF (MS vs. controls).
| Module ID | Pathway | |
|---|---|---|
| M1 | hsa04062 : chemokine signaling pathway | 7.7E–3 |
| hsa04060 : cytokine–cytokine receptor interaction | 1.5E–2 | |
| hsa04672 : intestinal immune network for IgA production | 3.8E–2 | |
| M2 | hsa05010 : Alzheimer’s disease | 3.0E–3 |
| hsa05014 : Amyotrophic Lateral Sclerosis (ALS) | 3.1E–2 | |
| hsa04720 : long-term potentiation | 4.0E–2 | |
| M4 | hsa04640 : hematopoietic cell lineage | 4.7E–6 |
| hsa04060 : cytokine–cytokine receptor interaction | 1.4E–4 | |
| hsa04210 : apoptosis | 8.6E–4 | |
| hsa05020 : prion diseases | 2.1E–2 | |
| hsa05332 : graft-versus-host disease | 2.3E–2 | |
| hsa04940 : type I diabetes mellitus | 2.5E–2 | |
| M7 | hsa00590 : arachidonic acid metabolism | 3.3E–2 |
| M9 | hsa04620 : toll-like receptor signaling pathway | 1.7E–5 |
| M13 | hsa05217 : basal cell carcinoma | 2.3E–3 |
| hsa04340 : hedgehog signaling pathway | 2.3E–3 | |
| M14 | hsa04010 : MAPK signaling pathway | 1.5E–2 |
| M15 | hsa04110 : cell cycle | 1.2E–2 |
| M20 | hsa04115 : p53 signaling pathway | 3.3E–10 |
| hsa04110 : cell cycle | 2.5E–8 | |
| hsa04914 : progesterone-mediated oocyte maturation | 1.8E–3 | |
| M22 | hsa04810 : regulation of actin cytoskeleton | 1.6E–2 |
| hsa04666 : Fc gamma R-mediated phagocytosis | 2.4E–2 | |
| hsa04530 : tight junction | 4.4E–2 | |
| M23 | hsa04144 : endocytosis | 1.5E–2 |
| hsa04540 : gap junction | 2.7E–2 | |
| M25 | hsa04510 : focal adhesion | 2.7E–2 |
| hsa04512 : ECM-receptor interaction | 3.1E–2 |
Modularity analysis.
The list of pathways enriched in modules for PBMCs (relapse vs. remission).
| Module ID | Pathway | |
|---|---|---|
| M1 | hsa04612 : antigen processing and presentation | 6.6E–8 |
| hsa05340 : primary immunodeficiency | 2.7E–2 | |
| hsa05332 : graft-versus-host disease | 3.0E–2 | |
| hsa02010 : ABC transporters | 3.4E–2 | |
| M7 | hsa04115 : p53 signaling pathway | 3.5E–3 |
| hsa04110 : cell cycle | 1.2E–2 | |
| M8 | hsa04623 : cytosolic DNA-sensing pathway | 2.5E–4 |
| hsa04622 : RIG-I-like receptor signaling pathway | 5.2E–4 | |
| hsa04620 : toll-like receptor signaling pathway | 1.5E–3 | |
| M9 | hsa04120 : ubiquitin mediated proteolysis | 2.3E–2 |
| M10 | hsa03050 : proteasome | 1.3E–9 |
| M11 | hsa03040 : spliceosome | 1.0E–3 |
| hsa04350 :TGF-beta signaling pathway | 4.1E–2 |
Clique analysis.
The list of complexes enriched for CSF and PBMCs.
| Gene symbol | Complex |
|---|---|
| PSMA3, PSMB1, PSMB3, PSMB9, PSME1, PSMD7 | Proteasome (ID:39, 192,193) |
| GPS2, NCOR2, TBL1X | SMRT complex (ID:58) |
| EED, EZH2, RBBP4 | Polycomb repressive complex 2,3 (PRC 2,3) (ID:105, 996,995), EED-EZH2 complex (ID:974) |
| CCNB1, CCNB2, CCND1, CDK1, CDKN1A | Cell cycle kinase complex CDC2 (ID:310) |
| CCND1,CCND3, CDKN1A | Cell cycle kinase complex CDK5 (ID:313) |
| CBX5, DSN1, ZWINT | Mis12 centromere complex (ID:1464) |
| CTNNA1, CTNNB1, SDCBP | SDCBP-CTNNB1-CTNNA1-CDH1 complex (ID:1839) |
| TUBA1A, TUBA1B, TUBA1C | 60S APC containing complex (ID:3008) |
| IGF2BP1, ILF2, NOLC1, RPLP2, RPS11, RPS16, SRPK1, TUBA1A, YBX1 | Nop56p-associated pre-rRNA complex (ID:3055) |
| MAP2K1, SFN, YWHAG | Ksr1 complex (Ksr1, Mek, 14-3-3, Mapk), EGF stimulated (ID:5909, 5886) |
| PSMA1, PSMA2, PSMA7, PSMB10, PSMB3, PSMD3, PSMD4 | Proteasome (ID: 38, 39, 181, 191, 192, 193, 194) |
| DHX15, PABPC1, PRPF19, SF3B3, SNRPB | Spliceosome (ID:351) |
| ACTB, ANXA6, MYH9, SPTAN1 | PA700-20S-PA28 complex (ID:437) |
| HNRNPH1, HNRNPM, PABPC1, PRPF19, SF3B3, SNRPB | C complex spliceosome (ID:1181) |
| CDC37, HSP90AB1, MAP3K3 | Kinase maturation complex 1 (ID:5199) |
| CDC37, HSP90AB1, IKBKE | TNF-alpha/NF-kappa B signaling complex 8 (ID: 5269) |
| CASP8 FADD FAS | FAS-FADD-CASP8 complex (ID: 5473, 5860), FAS-FADD-CASP8-CASP10 complex (ID: 5859), Death induced signaling complex DISC (ID: 5799, 5800) |
| ACTB, MYH9, SPTAN1 | Emerin complex 1 (ID: 5604) |
Figure 3Functional categories of the networks were visualized using the Enrichment map plugin of the Cytoscape.
Significant biological processes are represented by one node in (A) CSF QQPPI network. (B) PBMCs QQPPI network. Nodes’ sizes indicate the significance of the enrichment (p-value). Edges show gene overlap between nodes and thickness indicates the number of overlapping enriched genes.
Central genes.
The list of more central genes enriched in functional modules and complexes for CSF and PBMCs.
| Module/complex ID | Gene symbol |
|---|---|
| CSF(MS | |
| M13 | SMAD1 |
| M14 | STK4 |
| M15 | RB1 |
| M20 | CDKN1A, CDK1 |
| M22 | RAC1 |
| M23 | ARRB2, ARRB1 |
| M25 | FN1 |
| ID:39, 192,193 | PSMA3 |
| ID:105, 974,996,995 | EED, EZH2, RBBP4 |
| ID:310,313 | CDK1, CDKN1A |
| ID:1839 | CTNNB1, SDCBP |
| ID:3008 | TUBA1A |
| ID:3055 | SRPK1, YBX1, ILF2, RPS16 |
| ID:5909, 5886 | SFN, YWHAG |
| PBMCs (relapse | |
| M7 | CDK2 |
| M8 | IKBKE |
| M10 | PSMA1 |
| M11 | MYC |
| ID: 38, 39, 181, 191, 192, 193, 194 | PSMA1, PSMA2, PSMA7, PSMB3, PSMD3 |
| ID:1181 | HNRNPM |
| ID:437,5604 | ACTB |
| ID:5199, 5269 | CDC37, HSP90AB1, MAP3K3, IKBKE |
| ID: 5473, 5860, 5859, 5799, 5800 | CASP8,FAS |
Figure 4Nodes with high centrality measures which involved in significant biological pathways and their expression values.
More central nodes in (A) CSF QQPPI network. (B) PBMCs QQPPI network.
Figure 5Candidate markers involved in functional modules and complexes.
The functional enrichment of candidate markers in (A) CSF QQPPI network. (B) PBMCs QQPPI network. Modules and complexes illustrated by brown and blue dotted circles, respectively.